An Important Biomarker in Patients with Bell’s Palsy: Serum Calprotectin

<i>Background and Objectives</i>: This study aimed to examine the relationship between serum calprotectin levels and facial paralysis in patients with Bell’s palsy and to determine its prognostic significance. <i>Materials and Methods</i>: This study included 40 patients diag...

Full description

Saved in:
Bibliographic Details
Main Authors: Cihan Türker, Elif Emre, Süleyman Aydın, Mustafa Dalgıç, Deniz Baklacı
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/4/747
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849713747752386560
author Cihan Türker
Elif Emre
Süleyman Aydın
Mustafa Dalgıç
Deniz Baklacı
author_facet Cihan Türker
Elif Emre
Süleyman Aydın
Mustafa Dalgıç
Deniz Baklacı
author_sort Cihan Türker
collection DOAJ
description <i>Background and Objectives</i>: This study aimed to examine the relationship between serum calprotectin levels and facial paralysis in patients with Bell’s palsy and to determine its prognostic significance. <i>Materials and Methods</i>: This study included 40 patients diagnosed with Bell’s palsy and 20 healthy individuals as controls. The patients were categorized into three groups based on their response to treatment: complete response, partial response, and no response. Blood samples were taken before treatment and in the third month after treatment to measure C-reactive protein, white blood cell count, lymphocyte count, neutrophil count, neutrophil-to-lymphocyte ratio, and calprotectin levels. <i>Results</i>: Serum calprotectin levels were found to be elevated in patients with BP compared to the healthy controls; however, no significant correlation was observed between calprotectin levels and disease prognosis. <i>Conclusions</i>: The findings suggest that Bell’s palsy patients have elevated serum calprotectin levels compared to healthy individuals, indicating the potential use of calprotectin as a biomarker in Bell’s palsy. However, no significant difference in calprotectin levels was observed between patients with varying degrees of treatment response, suggesting that calprotectin may be limited in predicting disease prognosis.
format Article
id doaj-art-437542cabd1442aeb259094e3897277d
institution DOAJ
issn 1010-660X
1648-9144
language English
publishDate 2025-04-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-437542cabd1442aeb259094e3897277d2025-08-20T03:13:52ZengMDPI AGMedicina1010-660X1648-91442025-04-0161474710.3390/medicina61040747An Important Biomarker in Patients with Bell’s Palsy: Serum CalprotectinCihan Türker0Elif Emre1Süleyman Aydın2Mustafa Dalgıç3Deniz Baklacı4Department of Otolaryngology, Private Medical Hospital, Elazig 23040, TurkeyDepartment of Anatomy, Firat University Faculty of Medicine, Elazig 23200, TurkeyDepartment of Biochemistry, Firat University Faculty of Medicine, Elazig 23200, TurkeyDepartment of Otolaryngology, Ataturk State Hospital, Zonguldak 67030, TurkeyDepartment of Otolaryngology, Bulent Ecevit University Faculty of Medicine, Zonguldak 67000, Turkey<i>Background and Objectives</i>: This study aimed to examine the relationship between serum calprotectin levels and facial paralysis in patients with Bell’s palsy and to determine its prognostic significance. <i>Materials and Methods</i>: This study included 40 patients diagnosed with Bell’s palsy and 20 healthy individuals as controls. The patients were categorized into three groups based on their response to treatment: complete response, partial response, and no response. Blood samples were taken before treatment and in the third month after treatment to measure C-reactive protein, white blood cell count, lymphocyte count, neutrophil count, neutrophil-to-lymphocyte ratio, and calprotectin levels. <i>Results</i>: Serum calprotectin levels were found to be elevated in patients with BP compared to the healthy controls; however, no significant correlation was observed between calprotectin levels and disease prognosis. <i>Conclusions</i>: The findings suggest that Bell’s palsy patients have elevated serum calprotectin levels compared to healthy individuals, indicating the potential use of calprotectin as a biomarker in Bell’s palsy. However, no significant difference in calprotectin levels was observed between patients with varying degrees of treatment response, suggesting that calprotectin may be limited in predicting disease prognosis.https://www.mdpi.com/1648-9144/61/4/747Bell’s palsycalprotectinmarker
spellingShingle Cihan Türker
Elif Emre
Süleyman Aydın
Mustafa Dalgıç
Deniz Baklacı
An Important Biomarker in Patients with Bell’s Palsy: Serum Calprotectin
Medicina
Bell’s palsy
calprotectin
marker
title An Important Biomarker in Patients with Bell’s Palsy: Serum Calprotectin
title_full An Important Biomarker in Patients with Bell’s Palsy: Serum Calprotectin
title_fullStr An Important Biomarker in Patients with Bell’s Palsy: Serum Calprotectin
title_full_unstemmed An Important Biomarker in Patients with Bell’s Palsy: Serum Calprotectin
title_short An Important Biomarker in Patients with Bell’s Palsy: Serum Calprotectin
title_sort important biomarker in patients with bell s palsy serum calprotectin
topic Bell’s palsy
calprotectin
marker
url https://www.mdpi.com/1648-9144/61/4/747
work_keys_str_mv AT cihanturker animportantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT elifemre animportantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT suleymanaydın animportantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT mustafadalgıc animportantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT denizbaklacı animportantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT cihanturker importantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT elifemre importantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT suleymanaydın importantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT mustafadalgıc importantbiomarkerinpatientswithbellspalsyserumcalprotectin
AT denizbaklacı importantbiomarkerinpatientswithbellspalsyserumcalprotectin